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Abstract
Background: The aim of this study was to investigate whether the lymph node ratio (LNR) was associated with the
prognosis of patients, who underwent surgery for pathological N2 non-small cell lung cancer (NSCLC).
Methods: A total of 182 patients were diagnosed with pathological N2 disease and underwent complete resection
surgeries with systematic lymphadenectomies. We counted the number of positives and removed lymph nodes to
calculate a ratio between them (LNR). We also investigated the association between skip mediastinal lymph node
metastasis and survival.
Results: Univariate analysis of survival in patients with N2 NSCLC showed that the T factor, clinical N factor, and
LNR were significant prognostic factors. Multivariate analyses showed that the clinical N stage and LNR were
significant independent prognostic factors for patients with pathological N2 NSCLC. Patients with a clinical lymph
node status of 0 (cN0) and LNR ≤0.22 showed a significantly higher survival rate than patients with a cN1-2 and
LNR ≥0.22 and 5-year survival rates were 47.1 and 10.3%, respectively (p < 0.0001).
Conclusions: LNR is an important prognostic factor for poor outcome following surgery in patients with N2
disease. The combination of the LNR and cN status provides a valuable prognostic tool.
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Background
Non-small cell lung cancer (NSCLC) featuring clinical
mediastinal disease is not often amenable to complete
resection. The survival range among patients with stage
III NSCLC is associated with various prognostic factors,
suggesting that patients at the N2 stage are a heteroge-
neous group [1, 2]. The heterogeneity of NSCLC in-
volves multiple factors, including preoperative detection,
neoadjuvant therapy susceptibility, clinically unsuspected
N2 disease (the presence of ipsilateral mediastinal nodal
metastases), and the level or site and number, or both, of
involved mediastinal lymph nodes [1, 3]. Few reports
have evaluated the lymph node ratio (LNR) as a prog-
nostic factor for N1 and N2 NSCLC [4, 5]. Therefore we
investigated the correlation between LNR and prognosis
in patients with pathological N2 NSCLC.
Methods
Patients
The hospital records of 1839 consecutive patients who
underwent a complete NSCLC resection between 1990
and 2010 were reviewed and 227 patients with patho-
logical N2 disease were identified. Patients were ex-
cluded from the study if they underwent segmentectomy
or wedge resection of the lung and the number of
resected lymph nodes was ≤6, and patients who died
within 30 days of surgery or without enough clinico-
pathological and prognostic information were also
excluded. A total of 182 patients (127 men and 55
women), ranging in age from 36 to 89 years (median
age, 66 years), were included in this study. All of these
182 patients underwent initial operation. Patients were
diagnosed as having pathological N2 who underwent
surgically complete resection with a systematic lymph-
adenectomy. Lymph node metastasis was preopera-
tively diagnosed using computed tomography (CT)
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scan. Since 2004, we introduced fluoro-deoxyglucose-
positron emission tomography (FDG-PET), which was
used as a reference and performed on 48 patients. Me-
diastinal lymph nodes with a short axis of >1 cm (es-
pecially >1.5 cm for Station. 7) on CT and/or positive
uptake on FDG-PET were regarded as metastatic
lymph nodes. Lymph node biopsy through mediasti-
noscopy was not performed routinely and was per-
formed selectively in patients with clinical N2.
Twenty-eight of 182 patients were performed medias-
tinoscopy and 17 patients were diagnosed as having
clinical N2. For patients with clinical single-level N2
disease, we elected to perform initial operation. Mag-
netic resonance imaging (MRI) was routinely
employed for brain metastasis assessment. Patients
who died within 1 month after surgery or received
chemoradiotherapy before surgery were excluded from
the study. Follow-up information was obtained from
all patients through outpatient visits or telephone in-
terviews either with the patients, their relatives, or
primary physicians. The outcomes included the type
of recurrence and survival time. Patient demographics
and tumor characteristics are detailed in Table 1.
Lymph node ratio and lymph node dissection
Pathologists counted the number of lymph nodes by ob-
serving the membrane integrity, which meant that sev-
eral parts of the lymph node tissue were countered as
one lymph node. We counted the number of positive
and removed lymph nodes to calculate the LNR and in-
vestigated the association between skip mediastinal
lymph node metastasis, which is defined as the medias-
tinal lymph node metastasis without hilar lymph node
metastasis and survival. Five-year survival of high and
low LNR groups was calculated. Maximum difference of
5-year survival could be available when we set LNR of
0.22 as a cut-off.
Pathological examination
After localization and size measurement, the specimens
were serially sectioned (3–4 mm) using a cryostat em-
bedded and stained with standard hematoxylin and
eosin. The tumor node metastasis (TNM) stage was
assigned according to the American Joint Committee on
Cancer staging system, seventh edition. All patients
demonstrated macroscopically negative surgical margins.
Follow-up
Follow-up examinations included chest X-rays and blood
tests at 3-month intervals and an additional thoracic CT
scans at 6-month intervals. The median follow-up dur-
ation was 42 months (range, 12–127 months).
Table 1 Characteristics of patients with pathological N2 disease
Variables Number of patients %







Squamous cell carcinoma 50 27.5
Others 12 6.6
Clinical T and N status
T1 N0 49 26.9
T2 N0 51 28.0
T3 N0 3 1.7
T4 N0 2 1.1
T1 N1 5 2.8
T2 N1 11 6.0
T3 N1 3 1.6
T1 N2 21 11.5
T2 N2 25 13.8
T3 N2 12 6.6
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Statistical analysis
All data regarding continuous variables are expressed as
mean ± SD. Significant differences were assessed using
the t test for continuous variables and the χ2 test for cat-
egorical variables. Outcome measures included type of
recurrence and survival time. Analyses were performed
using the SAS software package (SAS Institute, Inc,
Cary, NC). A p value of <0.05 was considered statisti-
cally significant.
Results
Patient characteristics are summarized in Table 1. The
patients included 127 males and 55 females. Pathological
types included 120 adenocarcinomas, 50 squamous cell
carcinomas, and 12 other types of NSCLC. Clinical N
lymph node (cN) stages were diagnosed as N0 in 105 pa-
tients, N1 in 19, and N2 in 58. There were 59 patients
diagnosed as T1, 92 as T2, and 31 as T3. Skip medias-
tinal lymph node metastasis (N1 negative) was demon-
strated in 69 patients (37.9%), and mediastinal lymph
nodes metastasis with N1 disease (N1 positive) was
found in 113. A pneumonectomy was performed in 15
(8.3%) patients, bilobectomy in 19 (10.4%), and lobec-
tomy in 148 (81.3%). The median number of removed
nodes was 21, and the median number of positive nodes
was 3. The median LNR was 0.24. A univariate analysis
of survival in patients with N2 NSCLC showed that the
T factor (T1 or 2 vs. T3, p < 0.0001), cN factor (N0 vs.
N1 o r2, p = 0.0094), and LNR (≤0.22 vs. >0.22, p =
0.0056) were significant prognostic factors (Table 2). A
multivariate analysis showed that the cN stage (p =
0.0143) and LNR (p = 0.0071) were significant independ-
ent prognostic factors for patients with pathological N2
NSCLC (Table 3). The 5-year survival rate after surgery
according to the cN stage (N0 and N1–2) was 39.5 and
21.2%, respectively (Fig. 1a). The 5-year survival rate of
patients with an LNR of ≤0.22 was 40.2%; however, that
of patients with pathological N2 having an LNR of ≥0.22
showed a statistically significant poorer survival rate
(Fig. 1b). Figure 2 shows the comparison of survival
curves among the subgroup on the bias of cN stage and
LNR. Patients who had cN0 and an LNR of ≤0.22
showed a significantly higher survival rate than patients
with cN1-2 and LNR of ≥0.22 and the 5-year survival
rates were 47.1 and 10.3%, respectively (p < 0.0001).
Discussion
This retrospective study clarified the prognostic import-
ance of the LNR in patients with pathological N2
NSCLC, who underwent complete dissection of the me-
diastinal lymph nodes. Our results indicated that LNR
was an important prognostic factor for poor outcome
after surgery in patients with N2 disease.
The 5-year survival rate for patients with p-stage III
was 33.4% in the current series, which was consistent
with the Japanese Lung Cancer Registry Study results.
Several factors such as cN factor, N2 level, tumor size,
tumor location, and skip N2 are important postopera-
tive prognostic factors in patients with N2 disease [2,
6–10]. A single N2 disease showed favorable prognosis
compared to those with multiple N2 disease [2, 11],
and skip metastatic disease is a favorable N2 subset,
possibly because it is usually associated with single-
level N2 metastatic involvement [8, 12]. The present
study demonstrated that skip metastasis or single N2
Table 2 Survival of patients with N2 non-small cell lung cancer
by a univariate analysis (log-rank test)

























Table 3 Prognostic factors for overall survival retained in a
multivariate analysis
Variables Hazard ration 95% CI p value
Pathological T factor 1.301 1.020–1.643 0.0531
Histology 0.932 0.546–1.466 0.571
Clinical N stage 1.386 1.047–1.512 0.0143
Skip metastasis 0.722 0.487–0.988 0.123
Lymph node ratio 1.725 1.174–2.152 0.0071
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disease showed favorable prognoses, however, these dif-
ferences were not statistically significant. On the other
hand, Benoit et al. [13] reported that skip metastases
occur frequently in NSCLC and complete dissection of
the hilar and mediastinal lymph node should remain
the standard surgical procedure for this disease. How-
ever, skip metastasis is not an independent prognostic
factor for survival. Bria et al. [14] used the number of
high risk factors (HRFs) as the standard to divide pa-
tients into risk classes. HRFs included the LNR, sex,
stage, N status, grade, histology, age, and the number of
involved nodes.
In this study, cN stage was an independent prognostic
factor for patients with pathological N2 disease. Many
previous studies have reported significant associations
with survival for cN factors in patients with stage IIIA
NSCLC [2, 15, 16]. In our study, the mediastinal lymph
node sizes by CT scan and/or positive uptake by FDG-
PET were diagnosed as metastatic lymph nodes. Prenzel
et al. [17] described the difficulty of defining cut-off
values to diagnose metastasis, and also showed a signifi-
cant difference between the sizes of non-metastatic lymph
nodes and infiltrated nodes. PET scanning is highly sensi-
tive for the detection of mediastinal metastasis [18]. A
Fig. 1 Probability of survival of patients with N2 non-small cell lung cancer according to clinical lymph node status (a) and lymph node ratio (b)
Fig. 2 Overall survival rate for patients with N2 non-small cell lung cancer depends on clinical lymph node status (cN) and lymph node ratio
(LNR). cN0 and LNR ≤0.22 (black line). cN0 and LNR >0.22, or cN1-2 and LNR ≤0.22 (black dashed line). cN1-2 and LNR > 0.22 (gray line)
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controlled multicenter clinical study reported that FDG-
PET improved diagnosis precision for mediastinal lymph
nodes [19]. One of the limitations of the present study
was that PET-scanning was initiated in 2004, and not all
cases were examined using this method.
The number of involved lymph nodes that were identi-
fied depended on the number of lymph nodes removed
and examined, which in itself depended on surgical and
pathological procedures. In cases where few nodes were
removed, the N stage could not be accurately classified.
To improve the prognostication system, the LNR, which
takes into account not only the number of positive
nodes but also the number of nodes examined, removed
the variability in nodal assessment.
Our results were also consistent with the findings of
several recent studies evaluating the relationship between
the LNR and survival for colon, breast, gastric, and blad-
der cancers, which further support the validity of our find-
ings. The most recent TNM staging system for breast and
gastric cancers suggested that the number of involved
nodes has a significant prognostic value [20–23].
Limitations of the present study included the retro-
spective nature of the analysis, and adjuvant chemother-
apy for N2 disease was not routinely performed for all
patients. Therefore, it was difficult to evaluate the effect
of adjuvant chemotherapy on prognosis.
Conclusions
In conclusion, data regarding the LNR or cN status could
be used to provide a more accurate prognosis in patients
with resected N2 NSCLC. The combination of the LNR
and cN status provides a valuable prognostic tool. These
findings have potential for predicting the best therapeutic
modalities for patients with pathological N2 disease.
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